Professional Education

  • Doctor of Medicine, CUNY Mount Sinai School Medicine (2006)
  • Bachelors of Art, UC Berkeley, Molecular Cell Biology (2002)

Stanford Advisors

Research & Scholarship

Current Research and Scholarly Interests

Multi-modality imaging of the aortic valve with 3-D echochardiography and computed tomography. Strain quantification of LV wall motion with speckle tracking imaging (STI) and tissue Doppler imaging (TDI).


Journal Articles

  • Five-year experience with percutaneous closure of patent foramen ovale AMERICAN JOURNAL OF CARDIOLOGY Slavin, L., Tobis, J. M., Rangarajan, K., Dao, C., Krivokapich, J., Liebeskind, D. S. 2007; 99 (9): 1316-1320


    Patent foramen ovale (PFO) has been implicated in the pathogenesis of cryptogenic stroke, arterial desaturation, decompression illness, and migraine headache (MH). This study evaluated the safety of percutaneous transcatheter PFO closure in patients with cryptogenic stroke, transient ischemic attack, or arterial desaturation. Additionally, symptomatic reduction in MH was determined after interatrial shunt closure. Of the 252 patients referred to the University of California, Los Angeles, with PFO, 131 underwent closure of the interatrial communication with a CardioSEAL (n = 30) or Amplatzer (n = 101) device. PFO morphology was evaluated with transesophageal echocardiography. Follow-up was conducted at 1 to 2 months with echocardiography, with clinical assessment annually thereafter. At an average follow-up of 30 months, there was no recurrence of any thromboembolic event (transient ischemic attack, stroke, or peripheral). There was a reduction in MH, defined as the complete resolution of headache or a >50% reduction in the number of headache days, in 85% of patients after PFO closure. Temporary problems after device implantation, including chest discomfort and palpitations, were reported in 23% of patients and occurred more frequently in patients with nickel hypersensitivity (p <0.05). In conclusion, transcatheter PFO closure is an effective and safe therapeutic modality in the prevention of thromboembolic events and MH associated with interatrial shunting in patients who present with cryptogenic stroke. Pending randomized, controlled trials are necessary to determine if this invasive approach is preferable to medical therapy for the prevention of recurrent stroke or as primary treatment for patients with MH.

    View details for DOI 10.1016/j.amjcard.2006.12.054

    View details for Web of Science ID 000246168600029

    View details for PubMedID 17478165

  • Association of interatrial shunts and migraine headaches - Impact of transcatheter closure JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY Azarbal, B., Tobis, J., Suh, W., Chan, V., Dao, C., Caster, R. 2005; 45 (4): 489-492


    To examine the relationship between patent foramen ovale (PFO) or atrial septal defect (ASD) with the incidence of migraine headache (MHA) and assess whether closure of the interatrial shunt in patients with MHA would result in improvement of MHA.Migraine headache is present in 12% of adults and has been associated with interatrial communications. This study examined the relationship between PFO or ASD with the incidence of MHA and assessed whether closure of the interatrial shunt in patients with MHA would result in improvement of MHA.A sample of 89 (66 PFO/23 ASD) adult patients underwent transcatheter closure of an interatrial communication using the CardioSEAL (n = 22), Amplatzer PFO (n = 43), or the Amplatzer ASD (n = 24) device.Before the procedure, MHA was present in 42% of patients (45% of patients with PFO and 30% of patients with ASD). At three months after the procedure, MHA disappeared completely in 75% of patients with MHA and aura and in 31% of patients with MHA without aura. Of the remaining patients, 40% had significant improvement (>or=2 grades by the Migraine Disability Assessment Questionnaire) of MHA.Transcatheter closure of PFO or ASD results in complete resolution of MHA in 60% of patients (75% of patients with migraine and aura) and improvement in symptoms in 40% of the remaining patients. Interatrial communications may play a role in the etiology of MHA either through paradoxic embolism or humoral factors that escape degradation in bypassing the pulmonary circulation. A randomized trial is needed to determine whether transcatheter closure of interatrial shunts is an effective treatment for MHA.

    View details for DOI 10.1016/j.jacc.2004.09.075

    View details for Web of Science ID 000227102300004

    View details for PubMedID 15708691

Footer Links:

Stanford Medicine Resources: